سعر Ranxapin 10 mg 10 tabs. 2026

Olanzapine 10 mg tablets (Ranxapin, Future Pharmaceutical Industries > Sun Pharma Egypt); the 10-tablet pack named in the source file was not found in the directories opened (7- and 21-tablet packs are listed).

• Schizophrenia, including maintaining clinical improvement during continuation therapy in initial responders.Population: Adultselectronic medicines compendium (emc)
• Moderate to severe manic episode.Population: Adultselectronic medicines compendium (emc)
• Prevention of recurrence in bipolar disorder in patients whose manic episode responded to olanzapine.Population: Adultselectronic medicines compendium (emc)

• Very common: weight gain, somnolence, orthostatic hypotension, elevated plasma prolactin.International label, same formulation · electronic medicines compendium (emc)
• Common: eosinophilia, leukopenia, neutropenia, elevated cholesterol, glucose and triglycerides, glucosuria, increased appetite, dizziness, akathisia, parkinsonism, dyskinesia, mild anticholinergic effects (constipation, dry mouth), transient raised ALT/AST, rash, asthenia, fatigue, oedema, pyrexia, arthralgia, sexual dysfunction.International label, same formulation · electronic medicines compendium (emc)
• Uncommon/rare: diabetes with ketoacidosis or coma, seizures, tardive dyskinesia, bradycardia, QTc prolongation, thromboembolism, photosensitivity, alopecia, urinary incontinence/retention; NMS, pancreatitis, hepatitis, rhabdomyolysis, ventricular arrhythmias/sudden death, DRESS (not known).International label, same formulation · electronic medicines compendium (emc)

• Hypersensitivity to olanzapine or any excipient.International label, same formulation · electronic medicines compendium (emc)
• Patients with known risk of narrow-angle glaucoma.International label, same formulation · electronic medicines compendium (emc)

• Not recommended in dementia-related psychosis and/or behavioural disturbances: increased mortality and cerebrovascular adverse events in elderly patients.International label, same formulation · electronic medicines compendium (emc)
• Neuroleptic malignant syndrome: discontinue all antipsychotics if signs develop.International label, same formulation · electronic medicines compendium (emc)
• Hyperglycaemia/diabetes (occasionally with ketoacidosis or coma), weight gain and adverse lipid changes: monitor glucose, weight and lipids.International label, same formulation · electronic medicines compendium (emc)

• Fluvoxamine, ciprofloxacin and other CYP1A2 inhibitorsIncrease olanzapine levels (fluvoxamine raised AUC by 52-108%); consider a lower starting dose.electronic medicines compendium (emc)
• Smoking, carbamazepine (CYP1A2 inducers)May reduce olanzapine concentrations; monitor and consider dose increase.electronic medicines compendium (emc)
• Activated charcoalReduces oral bioavailability by 50-60%; separate by at least 2 hours.electronic medicines compendium (emc)

• No adequate and well-controlled studies in pregnant women; use only if potential benefit justifies the potential risk to the foetus.International label, same formulation · electronic medicines compendium (emc)
• Excreted in breast milk (infant exposure about 1.8% of the maternal weight-adjusted dose); patients should not breast-feed while taking olanzapine.International label, same formulation · electronic medicines compendium (emc)

• Olanzapine: Broad receptor profile with affinity for serotonin 5-HT2A/2C, 5-HT3, 5-HT6, dopamine D1-D5, muscarinic M1-M5, alpha-1 adrenergic and histamine H1 receptors; greater 5-HT2 than D2 activity (UK SmPC).